20/20 Biolabs, Inc. Common Stock (AIDX) — Cash Flow Quality Index
20/20 Biolabs, Inc. Common Stock (AIDX) has a Cash Flow Quality Index of 2.65x as of December 2022. Operating cash flow of $5.80 Million exceeds net income of $2.19 Million, indicating high earnings quality where cash backs reported profits. Also explore 20/20 Biolabs, Inc. Common Stock asset portfolio for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
20/20 Biolabs, Inc. Common Stock Cash Flow Quality Index (2021–2022)
Historical Cash Flow Quality Index for 20/20 Biolabs, Inc. Common Stock across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check tangible net worth ratio of 20/20 Biolabs, Inc. Common Stock to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for 20/20 Biolabs, Inc. Common Stock (2021–2022)
Year-by-year earnings quality comparison for 20/20 Biolabs, Inc. Common Stock. For live market cap and the full company financial profile, see AIDX stock market capitalisation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2022 | 2.65x | $5.80 Million | $2.19 Million | ▲ +611.9% |
| 2021 | -0.52x | $-1.07 Million | $2.07 Million | — |